Joseph P. Hagan

Biography

Mr. Joseph P. Hagan, also known as Jay, has been the Chief Executive Officer and President of Regulus Therapeutics Inc. since May 4, 2017. Mr. Hagan served as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer of Regulus Therapeutics Inc. since joining it on January 4, 2016 until May 4, 2017. Mr. Hagan is the Founder of Access Bioventures. He served as a Consultant of Orexigen Therapeutics, Inc. since December 12, 2015 until December 11, 2016. He served as the Chief Business & Financial Officer of Orexigen Therapeutics, Inc. since February 2015 until December 11, 2015 and served as its Treasurer until December 11, 2015. He served as Executive Vice President and Principal Accounting Officer at Orexigen Therapeutics, Inc., and also served as Acting Chief Financial Officer since March 2011 and Chief Business Officer since June 2011. Mr. Hagan served as Senior Vice President of Corporate Development, Strategy, Communications, & Technical Operations at Orexigen Therapeutics from May 2009 to June 2011. Prior to Orexigen, he worked at Amgen, from September 1998 to April 2008, where he served in various senior business development roles, including Founder, President and Managing Director of Amgen Ventures. He joined Amgen Ventures in 1998 and oversaw and directed the fund's investment in early-stage biotechnology companies focused on discovering and developing human therapeutics. Mr. Hagan served as the Director of Corporate Development at Amgen, where he held responsibility for mergers and acquisitions, as well as support of significant corporate driven alliance initiatives. He has led a number of notable transactions including the acquisitions of Tularik and Immunex as well as the sale of the Novantrone business. Before joining Amgen, Mr. Hagan spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences, where he served as a Biochemical Engineer.  

Research Interest

 business